Tucatinib Improves PFS, OS in HER2+ BC With Brain Metastases Tucatinib Improves PFS, OS in HER2+ BC With Brain Metastases
In HER2-positive breast cancer patients with brain metastases treated with trastuzumab and capecitabine, tucatinib increased median overall survival from 12 months to 18.1 months in a phase 2 trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | Hematology | HER2 | Herceptin | Neurology | Xeloda